---
document_datetime: 2025-12-29 14:35:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/solymbic.html
document_name: solymbic.html
version: success
processing_time: 0.1093887
conversion_datetime: 2025-12-30 09:12:40.629363
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Solymbic

[RSS](/en/individual-human-medicine.xml/65895)

##### Withdrawn

This medicine's authorisation has been withdrawn

adalimumab Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Solymbic](#news-on)
- [Related content](#related-content-557)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 June 2018, the European Commission withdrew the marketing authorisation for Solymbic (adalimumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amgen Europe B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Solymbic was granted marketing authorisation in the EU on 22 March 2017 for treatment of rheumatoid arthritis, enthesitis-related arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and non-infectious uveitis.

Solymbic is a biosimilar medicine of Humira. There are other biosimilar medicinal products of Humira authorised and marketed in the EU. Solymbic was a duplicate application to Amgevita, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Amgevita.

The European Public Assessment Report (EPAR) for Solymbic is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Solymbic : EPAR - Summary for the public

English (EN) (580.37 KB - PDF)

**First published:** 07/04/2017

**Last updated:** 07/04/2017

[View](/en/documents/overview/solymbic-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-538)

български (BG) (665.09 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/bg/documents/overview/solymbic-epar-summary-public_bg.pdf)

español (ES) (559.95 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/es/documents/overview/solymbic-epar-summary-public_es.pdf)

čeština (CS) (640.44 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/cs/documents/overview/solymbic-epar-summary-public_cs.pdf)

dansk (DA) (554 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/da/documents/overview/solymbic-epar-summary-public_da.pdf)

Deutsch (DE) (563.02 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/de/documents/overview/solymbic-epar-summary-public_de.pdf)

eesti keel (ET) (552.38 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/et/documents/overview/solymbic-epar-summary-public_et.pdf)

ελληνικά (EL) (671.55 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/el/documents/overview/solymbic-epar-summary-public_el.pdf)

français (FR) (561.6 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/fr/documents/overview/solymbic-epar-summary-public_fr.pdf)

hrvatski (HR) (580.59 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/hr/documents/overview/solymbic-epar-summary-public_hr.pdf)

italiano (IT) (556.94 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/it/documents/overview/solymbic-epar-summary-public_it.pdf)

latviešu valoda (LV) (275.58 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/lv/documents/overview/solymbic-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (584.96 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/lt/documents/overview/solymbic-epar-summary-public_lt.pdf)

magyar (HU) (633.6 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/hu/documents/overview/solymbic-epar-summary-public_hu.pdf)

Malti (MT) (628.45 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/mt/documents/overview/solymbic-epar-summary-public_mt.pdf)

Nederlands (NL) (558.9 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/nl/documents/overview/solymbic-epar-summary-public_nl.pdf)

polski (PL) (639.92 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/pl/documents/overview/solymbic-epar-summary-public_pl.pdf)

português (PT) (559.5 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/pt/documents/overview/solymbic-epar-summary-public_pt.pdf)

română (RO) (588.68 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/ro/documents/overview/solymbic-epar-summary-public_ro.pdf)

slovenčina (SK) (624.71 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sk/documents/overview/solymbic-epar-summary-public_sk.pdf)

slovenščina (SL) (615.65 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sl/documents/overview/solymbic-epar-summary-public_sl.pdf)

Suomi (FI) (553.67 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/fi/documents/overview/solymbic-epar-summary-public_fi.pdf)

svenska (SV) (554.21 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sv/documents/overview/solymbic-epar-summary-public_sv.pdf)

## Product information

Solymbic : EPAR - Product Information

English (EN) (2.42 MB - PDF)

**First published:** 07/04/2017

**Last updated:** 10/07/2018

[View](/en/documents/product-information/solymbic-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-368)

български (BG) (6.02 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/bg/documents/product-information/solymbic-epar-product-information_bg.pdf)

español (ES) (3.85 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/es/documents/product-information/solymbic-epar-product-information_es.pdf)

čeština (CS) (4.92 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/cs/documents/product-information/solymbic-epar-product-information_cs.pdf)

dansk (DA) (3.35 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/da/documents/product-information/solymbic-epar-product-information_da.pdf)

Deutsch (DE) (3.56 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/de/documents/product-information/solymbic-epar-product-information_de.pdf)

eesti keel (ET) (3.27 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/et/documents/product-information/solymbic-epar-product-information_et.pdf)

ελληνικά (EL) (6.23 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/el/documents/product-information/solymbic-epar-product-information_el.pdf)

français (FR) (3.98 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/fr/documents/product-information/solymbic-epar-product-information_fr.pdf)

hrvatski (HR) (3.68 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/hr/documents/product-information/solymbic-epar-product-information_hr.pdf)

íslenska (IS) (3.59 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/is/documents/product-information/solymbic-epar-product-information_is.pdf)

italiano (IT) (3.92 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/it/documents/product-information/solymbic-epar-product-information_it.pdf)

latviešu valoda (LV) (5.05 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/lv/documents/product-information/solymbic-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.84 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/lt/documents/product-information/solymbic-epar-product-information_lt.pdf)

magyar (HU) (5.02 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/hu/documents/product-information/solymbic-epar-product-information_hu.pdf)

Malti (MT) (5.28 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/mt/documents/product-information/solymbic-epar-product-information_mt.pdf)

Nederlands (NL) (3.65 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/nl/documents/product-information/solymbic-epar-product-information_nl.pdf)

norsk (NO) (3.45 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/no/documents/product-information/solymbic-epar-product-information_no.pdf)

polski (PL) (5.13 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/pl/documents/product-information/solymbic-epar-product-information_pl.pdf)

português (PT) (3.53 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/pt/documents/product-information/solymbic-epar-product-information_pt.pdf)

română (RO) (3.89 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/ro/documents/product-information/solymbic-epar-product-information_ro.pdf)

slovenčina (SK) (4.89 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/sk/documents/product-information/solymbic-epar-product-information_sk.pdf)

slovenščina (SL) (4.87 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/sl/documents/product-information/solymbic-epar-product-information_sl.pdf)

Suomi (FI) (3.75 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/fi/documents/product-information/solymbic-epar-product-information_fi.pdf)

svenska (SV) (3.54 MB - PDF)

**First published:**

07/04/2017

**Last updated:**

10/07/2018

[View](/sv/documents/product-information/solymbic-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG/0946 22/06/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Solymbic : EPAR - All Authorised presentations

English (EN) (514.38 KB - PDF)

**First published:** 07/04/2017

**Last updated:** 07/04/2017

[View](/en/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-517)

български (BG) (536.38 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/bg/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_bg.pdf)

español (ES) (508.28 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/es/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_es.pdf)

čeština (CS) (532.17 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/cs/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (511.23 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/da/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (508.32 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/de/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (505.94 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/et/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (549.49 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/el/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_el.pdf)

français (FR) (509.49 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/fr/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (511.79 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/hr/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (509.58 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/is/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_is.pdf)

italiano (IT) (513.63 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/it/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (193.56 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/lv/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (509.22 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/lt/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (522.74 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/hu/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (534.14 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/mt/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (507.42 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/nl/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (507.91 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/no/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_no.pdf)

polski (PL) (527.71 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/pl/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_pl.pdf)

português (PT) (508.73 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/pt/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_pt.pdf)

română (RO) (512.04 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/ro/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (525.69 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sk/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (520.52 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sl/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (514.13 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/fi/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (508.72 KB - PDF)

**First published:**

07/04/2017

**Last updated:**

07/04/2017

[View](/sv/documents/all-authorised-presentations/solymbic-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Solymbic Active substance adalimumab International non-proprietary name (INN) or common name adalimumab Therapeutic area (MeSH)

- Arthritis, Psoriatic
- Spondylitis, Ankylosing
- Crohn Disease
- Colitis, Ulcerative
- Hidradenitis Suppurativa
- Psoriasis
- Arthritis, Rheumatoid

Anatomical therapeutic chemical (ATC) code L04AB04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Please refer to section 4.1 of the Summary of product characteristics in the product information document.

## Authorisation details

EMA product number EMEA/H/C/004373

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 15/12/2016 Marketing authorisation issued 22/03/2017 Withdrawal of marketing authorisation 15/06/2018 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Solymbic : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.46 MB - PDF)

**First published:** 31/01/2018

**Last updated:** 10/07/2018

[View](/en/documents/procedural-steps-after/solymbic-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Solymbic : EPAR - Public assessment report

Reference Number: EMA/106921/2017

English (EN) (6.66 MB - PDF)

**First published:** 07/04/2017

**Last updated:** 07/04/2017

[View](/en/documents/assessment-report/solymbic-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Solymbic

Adopted

Reference Number: EMA/CHMP/41575/2017

English (EN) (559.71 KB - PDF)

**First published:** 27/01/2017

**Last updated:** 27/01/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-solymbic_en.pdf)

#### News on Solymbic

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2017) 27/01/2017

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

**This page was last updated on** 05/03/2019

## Share this page

[Back to top](#main-content)